Background: There are conflicting data regarding the benefits of omega-3 (n-3) fatty acids, most recently in patients with type 2 diabetes.
INTRODUCTION
Essential omega-3 (n-3) fatty acid supplementation is associated with improved endothelial and myocardial function and with triglyceride-lowering, anti-inflammatory, antithrombotic, and antiarrhythmogenic effects. High dietary intake of oily fish, and thus marine-derived n-3 fatty acids, is also associated with improved cardiovascular disease (CVD) outcomes. 1, 2 Several large randomized studies have shown significant improvements in mortality and a reduction in major CVD events after treatment with n-3 fatty acids. [3] [4] [5] Meta-analyses of such randomized studies have typically demonstrated a beneficial impact on CVD outcomes; however, there are inconsistencies in terms of methods
METHODS
This retrospective, matched-cohort study used data from the General Practice Research Database (GPRD; replaced by the Clinical Practice Research Datalink from April 2012). GPRD is a longitudinal, anonymized database derived from nearly 700 primary care practices throughout the United Kingdom that are broadly geographically and demographically representative of the country as a whole. At the time of the study, GPRD contained clinical records from Ͼ11 million individuals, of whom ϳ5 million were actively registered. The data captured by GPRD include demographic characteristics, medical history, clinical investigations, and drug prescriptions. The routine data are recorded electronically in general practice and monitored for quality by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Diagnoses in GPRD are recorded by using the Read code classification and have been validated in a number of studies, with results showing a high positive predictive value. 11 Studies using the GPRD/Clinical Practice Research Datalink are covered by ethics approval granted by the Trent Multicentre Research Ethics Committee (reference 05/MRE04/87). The current study was granted MHRA Independent Scientific Advisory Committee approval (ISAC 12_033).
Selection of Patients With a First MI
The study population comprised patients diagnosed with a first MI whose records had been assessed by the MHRA as meeting research-quality standards. To ensure that the first identified MI was indeed the first occurrence, patients were excluded if the description of the MI implied the existence of a previous infarction event, if patients had been registered at the practice for Ͻ180 days before the MI, or if the practice was judged by the MHRA to be recording up-to-standard data for Ͻ180 days before that event. Patients were selected if they were prescribed highly purified n-3 fatty acids approved in the United Kingdom for secondary prevention after MI at a daily dose of 1 g. Patients were excluded from the study if they were prescribed fishderived n-3 fatty acid preparations not licensed for post-MI secondary prevention at any time after their first MI. People with diabetes other than type 2 were excluded. A flow diagram illustrating patient selection is detailed in Figure 1 .
Treatment Cohort Selection and Comparative Analysis
From this general study population, a cohort was identified of patients exposed to 1 g of n-3 fatty acids for the first time on or after their first MI (the index date). We restricted our analysis to treatment initiation within the recommended time of 90 days 12 and conducted a sensitivity analysis on those initiating treatment with n-3 fatty acids within 14 days. Patients were excluded from the cohort if any prescription stipulated a daily dose of Ͼ1 g, which would imply an indication other than secondary prevention, or if the daily dose could not be determined. Patients were also excluded if they were prescribed n-3 fatty acids subsequent to a further cardiovascular event (Figure 1 ).
Matching Procedure
Each member of the exposed cohort was matched, at random, to 4 patients from the remaining study population who had experienced a previous MI and had not been exposed to n-3 fatty acids. They were matched on the following criteria: sex, year of birth (Ϯ2 years), year of first MI, smoking status, type 2 diabetes status, registration with a differing general practice (to minimize confounding by indication), and a period of follow-up from their first MI not less than the interval between first MI and first n-3 fatty acid prescription in the corresponding exposed patient (to minimize immortal time bias).
The primary end point for this study was all-cause mortality as recorded in GPRD. Mortality was identified from the Read codes recorded in GPRD and from linked Office of National Statistics (ONS) mortality records.
Modeled Comparison of Survival
To determine if there was any identifiable residual confounding and to allow for changes in treatment and other mortality/CVD risk factors after the initial MI event, time-dependent Cox models were used. This modeling was potentially important in accounting for differences after the index date, such as exposure to other cardiovascular risk-modifying medications (eg, statins).
Covariates considered for inclusion in the Cox models were age, sex, diabetes, systolic blood pressure, total cholesterol, body mass index, smoking status, lipid-lowering therapy, antiplatelet therapy, and antihypertensive therapy (incorporating use of ␤-blockers and drugs affecting the renin-angiotensin system). After a preliminary analysis, a number of covariates were selected and then included in all of the models. Year of n-3 fatty acid initiation was also included in the models to account for any temporal effects. Baseline morbidity was characterized using the Charlson comorbidity index. Subjects with missing data were automatically excluded, and the proportional hazards assumption was considered by evaluation of the Kaplan-Meier curves and analysis of the Schoenfeld residuals. Survival patterns were evaluated under a number of alternative scenarios, including: aspirin and clopidogrel monotherapy or combination therapy, individual statin type, baseline LDL-C subgroup, achieved LDL-C subgroup, and those who were ever or never diagnosed with type 2 diabetes. This latter scenario violated a theoretical assumption of the survival model 13 Patients at practices recording up-to-standard data for ≥180 days before first MI n = 106,788 Figure 1 . Patient flow diagram for selection of patients exposed to omega-3 fatty acids (n-3 FA). MI ϭ myocardial infarction. Table I . Baseline characteristics at first myocardial infarction for those with and without type 2 diabetes at baseline, exposed and nonexposed to omega-3 (n-3) fatty acids. 
RESULTS

Patients and Baseline Characteristics
We identified 2466 eligible first-MI patients subsequently exposed to n-3 fatty acids; 326 (13%) had a baseline diagnosis of type 2 diabetes. These patients were matched in a 1:4 ratio to similar patients who had not been prescribed n-3 fatty acids post-MI. In the nondiabetes group, the mean (SD) age was 63 (12) years, and 71% were male. The matching was appropriate, resulting in very similar characteristics (Table I) , although patients exposed to n-3 fatty acids had worse socioeconomic status, generally regarded as an indicator of increased mortality risk. 14 In those with previous type 2 diabetes, the duration of diabetes in the nonexposed cohort was arguably slightly longer, with a mean duration of 6.1 years versus 5.4 years (P ϭ 0.059); however, the matching procedure was otherwise consistent.
Treatment With Other Cardiovascular Risk-Modifying Treatments After MI
The majority of post-MI patients had concurrent treatment with lipid-lowering therapies, antihypertensives, and antiplatelets after their first MI. This varied slightly between the various comparator groups used in this study (Table II) : patients exposed to n-3 fatty acids had a greater likelihood of concurrent exposure to these treatments. Within 90 days in those without diabetes, 98% of exposed patients had received lipidlowering drugs versus 84% in the nonexposed patients (P Ͻ 0.0001); for antihypertensive agents, the proportions were 99% versus 87% (P Ͻ 0.0001), respec-tively, and for antiplatelet drugs, it was 98% versus 85% (P Ͻ 0.0001). Thus, it was necessary to account for these factors by using the multivariate, time-dependent models.
Time To Initiation of n-3 Fatty Acid Treatment
Of those patients treated with n-3 fatty acids, 82% had their treatment initiated in the 90 days after first MI, in line with recommendations and justifying the selection of these subjects for this study. 12 Figure 2 illustrates the cumulative percentage of time to treatment initiation from the first event. Those in the lower tertile of time to initiation were also selected for a sensitivity analysis look- 
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ing at early time to treatment initiation (range, 0 -13 days; median, 7 days). Excluded patients, prescribed licensed n-3 fatty acids but with initial exposure Ն90 days post-MI, represented 17.9% of patients.
Crude Survival Patterns
Overall, there were 1517 recorded deaths (12.5% of patients). Crude event rates differed according to diabetes status and n-3 fatty acid exposure status. In those exposed to n-3 fatty acids, the crude event rates were 61/1000 person-years for those with type 2 diabetes at baseline and 33/1000 person-years for those without diabetes at baseline. In those not exposed to n-3 fatty acids, the crude event rates were 90/1000 person-years for those with type 2 diabetes at baseline and 46/1000 person-years for those without. These data resulted in crude relative risk values of 0.708 (95% CI, 0.602-0.833; P Ͻ 0.0001) overall, and 0.686 (95% CI, 0.504 -0.934; P ϭ 0.0166) for those with diabetes and 0.724 (95% CI, 0.621-0.844; P Ͻ 0.0001) for those without diabetes, respectively (Table III) .
Adjusted Survival Patterns
All of the selected covariates were important in the model in specifying the risk of death, including expo-sure to all classes of cardiovascular risk-modifying agent ( Table IV) .
The adjusted hazard ratio (aHR) for all-cause mortality was consistently lower among those exposed to n-3 fatty acids, and materially did not differ among those with and without diabetes at baseline survey or in those who developed diabetes during follow-up (Figure 3) . When the models were restricted to those who initiated therapy within 14 days, the strength of association for those exposed to n-3 fatty acids seemed modestly stronger across the range of subgroups.
The fully specified, time-dependent Cox models evaluating n-3 fatty acid exposure within 90 days and within 14 days are detailed in Table IV . The aHRs for these two scenarios were 0.782 (95% CI, 0.641-0.995; P ϭ 0.0159) and 0.680 (95% CI, 0.481-0.961; P ϭ 0.0288), respectively. In those with type 2 diabetes at baseline, the aHR seemed modestly stronger compared with those without diabetes: 0.714 (95% CI, 0.454 -1.124; P ϭ 0.1453) when initiating n-3 fatty acids within 90 days and 0.597 (95% CI, 0.295-1.211; P ϭ 0.1532) when initiating within 14 days (Figure 3) .
The association between use of n-3 fatty acids and reduced mortality hazard remained constant at approximately -20%, regardless of time-dependent ad- Table III . Number of events and crude relative risk values for patients exposed and not exposed to omega-3 (n-3) fatty acids. (Figure 4) . In analyses stratified according to on-treatment LDL-C subgroup, there was no materially significant difference in observed survival benefit from n-3 fatty acids exposure (Figure 5) . Similarly, when the association between n-3 fatty acid exposure was compared among those receiving single or dual antiplatelet therapy, a consistent benefit was observed with n-3 fatty acid exposure. There was no evidence of any significant additional survival benefit in the excluded patients exposed to initial treatment with n-3 fatty acids after 90 days (aHR ϭ 1.281 [95% CI, 0.750 -2.190]; P ϭ 0.365; n exposed ϭ 538). It is worth noting that some of these patients were likely to have initiated n-3 fatty acids after a subsequent event.
Parameter
DISCUSSION
This real-world evaluation of clinical practice complements randomized trial data by demonstrating that treatment with licensed n-3 fatty acids was associated with reduced all-cause mortality when initiated early post-MI. Our data are concordant with the 20% re- duction in all-cause mortality reported in the GISSI-P trial. 4 In our study, treatment initiation with licensed, highly purified n-3 fatty acids within 90 days of MI was associated with a reduction in risk of all-cause mortality of 21.8%, independent of other cardiovascular risk-modifying treatments. Our data also demonstrated that earlier treatment initiation, within the 14 days after MI, seemed to increase survival benefit by as much as 40%, the inference being that n-3 fatty acid treatment should be initiated as soon as possible. The impact on outcome was similar in those with and without type 2 diabetes and independent of other evidencebased, secondary-prevention medication strategies. The European Society of Cardiology, the American Heart Association, and other national cardiac societies have evaluated the evidence and converged on a recommendation for post-MI patients to consume 1 g of n-3 fatty acids per day. [15] [16] [17] The current study confirms that, although not all UK patients receive licensed n-3 supplements post-MI, physicians are prescribing in line with the licensed indication and National Institute for Health and Clinical Evidence (NICE) guidelines, 12 with the majority of patients treated with n-3 fatty acids receiving them within 90 days and also being treated with other evidence-based cardiovascular riskmodifying therapies. Although the adjusted models accounted for variations in clinical factors and concomitant medication use, it would have been of interest to examine individuals exposed to n-3 fatty acids but not to the other treatments. For simplicity, we classified Analysis n-3 FA initiated within 90 days of MI n-3 FA initiated within 14 days of MI All patients (1) No DM at index (2) T2DM at index (3) Never T2DM (4) Ever T2DM (5) All patients (6) No DM at index (7) T2DM at index ( Table IV for model specification (n ϭ 12,178; P ϭ 0.016). 2. Subgroup analysis of (1) who had no history of diabetes mellitus (DM) before first MI (n ϭ 10,569; P ϭ 0.054). 3. Subgroup analysis of (1) who had evidence of type 2 DM (T2DM) before first MI (n ϭ 1609; P ϭ 0.145). 4. Subgroup analysis of (1) who had no evidence of T2DM at any time (n ϭ 9581; P ϭ 0.021). 5. Subgroup analysis of (1) who had evidence of T2DM at any time (n ϭ 2565; P ϭ 0.328). 6. Base analysis for all patients initiating n-3 FA within 14 days of first MI; see Table IV for model specification (n ϭ 4107; P ϭ 0.029). 7. Subgroup analysis of (6) who had no history of DM before first MI (n ϭ 3474; P ϭ 0.121). 8. Subgroup analysis of (6) who had evidence of T2DM before first MI (n ϭ 633; P ϭ 0.153). 9. Subgroup analysis of (6) who had no evidence of T2DM at any time (n ϭ 3152; P ϭ 0.056). 10. Subgroup analysis of (6) who had evidence of T2DM at any time (n ϭ 1010; P ϭ 0.398).
antihypertensive agents as a single drug class, but this class included drugs such as ␤-blockers, angiotensinconverting enzyme inhibitors, and angiotensin II receptor blockers that are typically used routinely in secondary prevention post-MI regardless of whether the patient is hypertensive.
This epidemiologic study also provides an important evidential adjunct to existing randomized data in that it illuminates some potential limitations in relevant randomized trial designs. The most recent studythe ORIGIN trial-showed no difference in those with dysglycemia exposed to treatment with n-3 fatty acids versus placebo. 9 However, as we found no benefit in patients who initiated their n-3 fatty acid treatment after the recommended 90-day period, the question remains whether this may have been the case for the patients recruited in ORIGIN, considering that no information related to the time of initiation of n-3 fatty acids post-MI was provided in the publication. Although our study had only small numbers in the type 2 diabetes group, we observed that the magnitude of effect was similar in those with diabetes and in those without for all-cause mortality.
Importantly, this study evaluated all-cause mortality as an end point and not CVD events. We believe this to be important because one of the principal mechanisms of action of n-3 fatty acids is thought to be their antiarrhythmogenic properties. 1 In almost all study scenarios, this represents a potential reporting bias in that the probability of experiencing a nonfatal MI event could therefore be increased in those exposed to n-3 fatty acids. Use of death as the outcome avoids this potential bias and also protects against the issue of competing risks.
This study had inherent limitations. Because study patients were not randomized to treatment, there could be confounding by indication (or allocation bias), and there will in all probability remain residual confounding (accounting for nonrecorded factors). Nonetheless, the matching method seemed to work well. However, two covariates (ONS mortality and socioeconomic status) were provided by GPRD only after the specific study patients had been identified and matched; thus, these factors could not be used in the matching process. Interestingly, the patients exposed to licensed n-3 fatty acids were of lower socioeconomic status. This may be associated with general practitioners being aware of the potential benefits of n-3 fatty acids and therefore prescribing treatment on the understanding that the patient may not otherwise be able or willing to access marine n-3 fatty acids through diet or otherwise. Indeed, in the Euroaction Study, only 11% of patients in general practice achieved their recommended level of n-3 fatty acids by dietary means. 18 We have not examined the association between n-3 fatty acids and major nonfatal cardiovascular events, such as further acute coronary syndrome, need for subsequent percutaneous coronary intervention or coronary artery bypass graft, or recurrence of angina or stroke; this association was outside the remit of this already extensive analysis. However, the results of GISSI-P and other studies would lead us to expect less of an effect on these outcomes with this dose of n-3 fatty acids. 4, 5, 19 In addition, when viewed from a data perspective, case ascertainment for recurrent events can be difficult to distinguish from a recording of medical history. Therefore, we selected an index event (first MI) and primary end point (any death), each of which could be identified with a high degree of confidence.
Recent trials, such as OMEGA and ORIGIN, and a meta-analysis have suggested a lack of benefit of n-3 fatty acids in secondary prevention of cardiovascular disease in different patient populations. 9, 20, 21 In part, it was postulated (methodologic differences aside) that this may reflect a lack of benefit against a background of intensive modern preventative therapy. In the current study, we report on 1517 deaths, almost 10 times more deaths than in the OMEGA trial (although the annual death rates were similar at 4.8% and 4.2%, respectively), suggesting our study is both representative and adequately powered. In the sensitivity analysis among those receiving dual antiplatelet therapy and those achieving low levels of LDL-C (Ͻ1.8 mmol/L), we observed no significant modification of the beneficial effect of n-3 fatty acid exposure on mortality (Figures 4 and 5) . Taken together, the current data suggest that when n-3 fatty acids are prescribed within 90 days (and in particular within 14 days) of an MI, this intervention offers additional protection against all-cause mortality on top of contemporary pharmacotherapy. In GPRD, linking to ONS mortality records increases the frequency of death events by ϳ10%. This has a subtle technical impact on this type of study in that it introduces a potential immortal time bias in a very small number of the nonexposed, matched patients because they were subsequently determined to have died before the matching patient was first exposed to the treatment of interest. These corresponding exposed and nonexposed subjects were excluded. A further, subtle limitation of these data relates to the date of the record of MI on the general practitioner's computerized systems. Although we have assumed that the general practitioner has recorded the correct date of the MI from the discharge letter or in discussion with the patient, it is plausible-if not likelythat some of the MI event dates referred to the date at which the general practitioner entered the data onto their system. This would have the impact of slightly shortening the calculated time to treatment initiation that we report here.
These findings have important treatment implications. First, they help explain why some of the clinical trials have resulted in conflicting and sometimes neutral findings. Although we did not examine for dose effects, the timing of administration of n-3 fatty acid treatment seems relevant for optimizing survival benefit in secondary-prevention patients post-MI. Very early administration after hospital admission of higher doses of the licensed n-3 fatty acids should be evaluated.
CONCLUSION
In routine clinical practice, early treatment with licensed n-3 fatty acids after a nonfatal MI was associated with a substantial reduction in risk of death, independent of other cardiovascular risk-modifying treatments, in patients with and without type 2 diabetes.
